Skip to content
My WebMD Sign In, Sign Up

PMS Health Center

Font Size
A
A
A

Low-Dose Birth Control Pill Treats Severe PMS

First Oral Contraceptive for PMDD May Be Approved for Sale Early Next Year
By
WebMD Health News

Aug. 31, 2005 -- A low-dose oral contraceptive that is not yet on the market may be an effective alternative to antidepressants for the treatment of severe premenstrual syndrome.

Researchers show that the unique birth control formulation worked better than placebo for treating women with premenstrual dysphoric disorder (PMDD).

Researchers from Yale University and other research centers concluded that the oral contraceptive is as effective as selective serotonin reuptake inhibitor (SSRI) antidepressants for preventing PMDD, although the two were not compared against each other.

The newly published study included 450 women with PMDD from across the country.

Yale University's Kimberly Yonkers, MD, who led the research team, reported significant symptom improvement in 48% of women with PMDD in the study who took the oral contraceptive vs. 36% of women taking placebo pills. The women were evaluated over the course of two menstrual cycles.

The findings are published in the September issue of the journal Obstetrics and Gynecology.

"I wouldn't say that this is better that antidepressants, but it does give women and their physicians another treatment option," Yonkers says. "Many women don't want to take SSRIs."

PMDD affects between 3% and 5% of menstruating women and is characterized by severe emotional and/or physical symptoms seen in the days or weeks prior to a women's period. These symptoms are similar to those seen with PMS yet significantly interfere with a woman's work and social functioning and often last longer and are more debilitating.

The SSRIs Prozac, Zoloft, and Paxil CR are approved by the FDA for the treatment of PMDD. Other SSRIs used to treat PMDD include Celexa, Effexor, and Buspar.

24 On, 4 Off

The study was funded by the oral contraceptive's manufacturer, Berlex Laboratories, which developed it as a treatment for PMDD.

Company spokeswoman Kimberly Schillace tells WebMD that Berlex is hoping to introduce the drug early next year, assuming it gets FDA approval. It will be sold under the brand name Yaz.

"We think Yaz could represent a real shift in the way PMDD is treated," she says. "Up until now women have had to rely on SSRIs to treat these symptoms. We think Yaz could be a terrific new option for women who are also looking for effective contraception."

Yaz is similar to another oral contraceptive marketed by Berlex under the brand name Yasmin, but there are important differences, Schillace says. Both contain a unique progestin that mimics the activity of a diuretic (water pill) used to treat the symptom of bloating or water retention seen in PMS.

But women who take Yaz get 24 days of active hormone followed by four days off hormones, instead of the standard 21 days of active hormone treatment followed by seven days of no hormone treatment.

Yonkers and colleagues says the shorter time off hormones offered by Yaz treatment may help women avoid severe menstrual-related symptoms.

"We know that women taking oral contraceptives often complain of symptoms like headaches, bloating, and other problems during the week that they are off hormones," she tells WebMD. "This has been broadly characterized as 'hormonal withdrawal.' It is total hypothesis at this point, but it may be that shortening the time off hormones may help women avoid this withdrawal."

Today on WebMD

Understanding Absence Periods
Slideshow
pelivic pain slideshow
Slideshow
 
Is Your Period Normal
Quiz
Woman eating ice cream
Article
 
10 Ways to Revitalize Slideshow
Slideshow
Woman with insomnia
Article
 
Birth Control Pills Weight Gain
Article
Girl To Woman Your Period And PMS
Article
 
Managing PMS Exercise And More
Article
Period Cramping Your Style
Video
 
Screening Tests for Women
Slideshow
Continuous Birth Control Pills Safety
Video